(Q34497896)

2 August 2017

1 reference

title

The potential use of selective 5-HT2C agonists in treating obesity (English)

1 reference

2 August 2017

0 references

Brian M Smith

1

1 reference

2 August 2017

William J Thomsen

series ordinal

2

1 reference

2 August 2017

Andrew J Grottick

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

15

1 reference

2 August 2017

3

1 reference

2 August 2017

257-266

1 reference

Prevalence and Trends in Obesity Among US Adults, 1999-2000

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Overweight, obesity, and health risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Actual Causes of Death in the United States, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Outcome success in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Meal patterning in rodents: psychopharmacological and neuroanatomical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Molecular, pharmacological and functional diversity of 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

5-HT2C receptor agonists as potential drugs for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

The role of 5-HT2C receptors in affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Indoline derivatives as 5-HT(2C) receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Azepinoindoles. I. Hexahydroazepino[4,5-b]indoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

m-Chlorophenylpiperazine decreases food intake in a test meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

5-HT2C receptor activation decreases appetite and body weight in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.257

10.1517/13543784.15.3.257

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference